Squalene Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Squalene Market Trends and Insights

Clean-Beauty Boom Boosting Plant and Bio-Fermented Supply

Growing consumer insistence on transparent, cruelty-free labels is forcing cosmetic majors to abandon shark-derived squalene, a shift that has catalyzed capital allocation into olive, amaranth, and fermentation routes. Enzymatic extraction now recovers 0.5-1.0% of squalene from vegetable feedstock, roughly double solvent yields, tightening the squalene market supply chain and improving sustainability credentials. Evonik’s PhytoSquene, launched in 2023 and compliant with European Pharmacopoeia, illustrates how clean-beauty preferences dovetail with pharmaceutical-grade requirements. French refiner Sophim raised USD 21.5 million in 2023 to double olive-based capacity, responding to cosmetics and food players willing to pay 20-30% premiums for verified plant origin. Major beauty retailers now oblige suppliers to state squalene provenance on labels, effectively excluding shark sources even where law does not yet impose an outright ban. Industry observers expect shark-oil’s contribution to global supply to fall below 10% by 2028 as brands preempt reputational risk. 

Accelerating Use in Next-Gen Vaccine Adjuvants

Squalene-containing adjuvants such as MF59 and Sepivac SWE have validated safety at scale, encouraging government stockpiles for pandemic-preparedness. Seqirus’s MF59 appears in more than 100 million administered flu vaccine doses, providing a regulatory benchmark that late-stage COVID-19 and universal influenza candidates are following. Microfluidic manufacturing, demonstrated in 2024, shortens batch time to seven hours and delivers 200-liter GMP emulsions, producing material for 5 million doses while lowering capital intensity for contract manufacturers by 40%. These efficiencies position decentralized facilities in emerging markets to meet surging demand without heavy investment. Early-phase oncology immunotherapies are also trialing squalene adjuvant systems that stimulate T-cell responses, hinting at broader pharmaceutical uptake. If regulatory approvals accelerate, pharmaceutical-grade offtake could exceed current forecasts and stretch capacity in the squalene market.

Synthetic-Biology Cost Curve Crossing Shark-Oil Pricing

Fermentation processes now deliver cosmetic-grade material at USD 50-70 per kg, matching or undercutting marine supply when compliance and ethical costs are considered. Amyris’s Barra Bonita plant in Brazil, retaining 1.8 million liter capacity after a 2026 line expansion, showcases economic viability despite Chapter 11 restructuring. Croda’s 2023 licensing of Amyris technology secures pharmaceutical-grade batches that avoid peroxide and heavy-metal purification steps required for shark-oil, trimming USD 20-30 per kg relative downstream expenses. Academic metabolic-engineering studies reach lab yields of 2-4 g/L in engineered cyanobacteria, and scale-up could drive cost to USD 30-40 per kg by 2028. Continuous drops in biosynthetic cost therefore tighten price dispersion among all sustainable grades in the squalene market. 

Regulatory Tailwinds Banning Shark-Sourced Ingredients

CITES restricted liver-oil trade for deep-sea sharks in 2025, adding paperwork hurdles that disincentivize exporters. Taiwan and Australia mandate origin declarations that de facto eliminate shark-based imports, while the European Union’s cosmetics rules require ingredient transparency, letting consumer pressure do the rest. In the United States, policy think-tanks such as the National Security Commission on Emerging Biotechnology cast 2.7 million-shark annual harvests as a supply-chain risk, foreshadowing possible federal constraints^{[1]National Security Commission on Emerging Biotechnology, “Bio-Manufacturing Supply-Chain Report,” nsceb.gov} . This regulatory momentum favors vegetable and biosynthetic capacity, further driving the squalene market toward sustainable sources. 

Climate-Linked Volatility in Olive and Amaranth Feedstock Pricing

Mediterranean droughts cut Spanish and Italian olive yields during 2023-2024, lifting feedstock costs and squeezing refiners without long-term contracts^{[2]OECD-FAO, “Agricultural Outlook 2024-2033,” oecd-fao.org} . Amaranth harvests in the Andes fluctuate 20-30% year on year, compelling processors to carry costly inventory buffers. Meanwhile, 16% of global vegetable oil now flows into biodiesel, diverting raw materials that could otherwise become squalene. The dual shocks of climate and biofuel demand can compress cosmetic-grade margins by 15-25% within a quarter. Unless drought-resistant cultivars scale quickly, price volatility will remain a near-term headwind for the squalene market.

Global Fermentation-Grade Sugar Price Spikes (Biofuel Competition)

Brazil’s RenovaBio and India’s E20 mandate channel sugarcane toward ethanol, tightening sucrose availability for biochemical fermentation. Elevated sugar costs have already forced Amyris to test molasses and bagasse hydrolysates, but added pretreatment lifts unit cost USD 5-10 per kg. Because GMP revalidation takes at least a year, producers cannot easily switch feedstocks without delaying pharmaceutical deliveries. Elevated sugar prices are thus a structural restraint on biosynthetic expansion and can temper the upside potential of the squalene market over the medium term.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Source: Vegetable and Biosynthetic Grades Ascendant

Vegetable-source squalene represented 38.22% of squalene market share in 2025 and is projected to advance at a 6.96% CAGR, outperforming animal-derived supply. Expansion by olive refiners in Spain and France and amaranth processors in Argentina and Peru is supported by capital aimed at meeting GMP requirements for both cosmetic and pharmaceutical channels. The squalene market size for vegetable source is therefore set to climb steadily as retail mandates solidify plant-only positioning in prestige beauty. 

Biosynthetic is growing already indispensable for vaccine adjuvants. Amyris’s 1.8 million-liter Barra Bonita footprint anchors global supply agreements with Croda, which uses the feedstock for pharmaceutical-grade emulsions. Ongoing metabolic-engineering breakthroughs promise even greater yields that can trim cost curves further. Conversely, animal-source share is shrinking under CITES trade limits and consumer backlash. As more jurisdictions legislate origin labeling, shark-oil segments will continue to decline, reinforcing a structural pivot toward sustainable feedstocks in the squalene market.

By Purity Grade: Cosmetic Volume vs. Pharmaceutical Margin

Cosmetic grade comprised 68.85% of 2025 volume and is on course for a 6.58% CAGR. Reformulation away from shark oil has pushed legacy and indie brands alike to specify olive, amaranth, or biosynthetic grades, turning supply transparency into a selling point on retail shelves. Sustainable positioning supports price resilience even when raw-material costs rise. 

The squalene market size for pharmaceutical grade is also projected to widen as adjuvant stockpiles increase and oncology nano-delivery trials progress. Croda’s and Evonik’s GMP lines meet European Pharmacopoeia standards, giving them pricing leverage especially during vaccine surges. Food grade is expanding into nutraceutical softgels and fortification, but total uptake remains modest relative to topical cosmetics.

By End-user Industry: Cosmetics Lead, Pharma Gains Momentum

Cosmetics captured 70.12% share of the overall squalene market size in 2025, expanding at a 6.64% CAGR through 2031. Anti-aging serums, moisturizers, and hair-care treatments value squalene’s emollient and oxidative-stability properties, and ingredient-disclosure requirements are nudging even mass brands into sustainable sources. 

Pharmaceutical usage is smaller but rising swiftly. MF59, Sepivac SWE, and new TLR-agonist systems underline growth potential in both pandemic preparedness and immuno-oncology. If even a few pipeline candidates win approval, the squalene market share for pharmaceutical end users could climb significantly, absorbing much of the forthcoming biosynthetic capacity. Food, lubricant, and specialty-chemical applications remain niche but deliver diversification upside, especially where squalene’s thermal stability outperforms petro-based analogs.

Geography Analysis

Europe held 42.08% squalene market share in 2025, anchored by legacy olive supply chains in Spain, Italy, and France and by GMP plants serving vaccine hubs. The EU cosmetics rulebook obliges INCI transparency, favoring plant or biosynthetic inputs over shark derivatives, and regional refiners such as Sophim have expanded to capture both cosmetic and food verticals. Evonik’s PhytoSquene award underscores Europe’s commitment to pharmaceutical-grade innovation.

North America benefits from clean-beauty enthusiasm and government assessments framing biosynthetic squalene as a strategic asset. Nearshoring of vegetable refining into Mexico adds logistical resilience, while U.S. firms monitor potential regulatory shifts that could mirror Europe’s stricter stance on animal sourcing.

Asia-Pacific is the fastest-growing region, advancing at 6.79% CAGR through 2031. Chinese, Indian, and Korean brands are incorporating plant-based and biosynthetic squalene into affordable SKUs, widening addressable volume. India’s vaccine-manufacturing expansion seeks cost-effective GMP squalene, and local fermentation clusters can meet both domestic and export demand. Japanese and South-Korean premium brands employ squalene to cement skin-compatible reputations, while Southeast Asian nations explore palm and coconut-based extraction despite lower yields.

South America merges Brazil’s fermentation leadership with Argentina’s and Peru’s amaranth agriculture. Amyris’s plant signals export potential if feedstock costs stabilize. Middle-East and Africa currently import most requirements, yet vaccine facility build-outs in Saudi Arabia and Egypt imply future pharmaceutical-grade demand.

Regulatory Landscape

Squalene used in cosmetics is primarily governed by product safety and ingredient disclosure frameworks rather than substance bans. In the European Union, cosmetic uses fall under Regulation (EC) No 1223/2009 (consolidated text updated through April 2024), where squalene is not broadly listed as a prohibited or restricted cosmetic substance; however, animal-origin sourcing can introduce additional compliance obligations, including traceability and controls linked to animal by-product rules (e.g., Regulation (EC) No 1069/2009). Separately, EEA chemical compliance under REACH can apply to manufacturers and importers based on tonnage, which affects documentation and data requirements for supply into Europe.

In the United States, squalene has a long safety record in personal care, supported by the Cosmetic Ingredient Review (CIR) Expert Panel (affirmed in 2019). FDA oversight depends on intended use and claims (cosmetic versus drug), and for pharmaceutical and vaccine-adjuvant applications, substance identification and quality expectations (including established identifiers such as UNII listings and pharmacopeial alignment) place more weight on GMP controls, impurity profiles, and batch consistency. This quality framework reinforces the market shift toward traceable plant-derived and biosynthetic supply chains.

Value Chain Analysis

Upstream supply starts with feedstocks that shape both sustainability credentials and impurity burdens. Shark liver oil offers high squalene concentration but requires more intensive purification due to potential persistent organic pollutants and heavy metals. By contrast, plant sources (olive, amaranth and other vegetable oils) and fermentation routes deliver lower native concentration but provide stronger provenance control. Extraction and primary processing typically include crushing/refining of oils, solvent or enzymatic recovery, and initial concentration steps, and enzymatic approaches are increasingly used to improve recovery efficiency from vegetable streams. Fermentation-based production also depends on carbohydrate inputs and engineered strains, followed by downstream purification to reach cosmetic, food, or pharmaceutical specifications.

Midstream conversion and qualification are dominated by GMP and pharmacopeial requirements for parenteral-grade material used in vaccine adjuvants. Quality systems, validated purification, and documentation become key bottlenecks. Evonik's plant-based, GMP-grade PhytoSquene, aligned with European Pharmacopoeia expectations, illustrates what qualifies for this stage, as does Croda's exclusive license agreement with Amyris (signed in 2023) to secure biotechnology-derived, pharmaceutical-grade squalene for vaccine-adjuvant supply chains. Downstream channels then split into cosmetics, where retailers and brand policies increasingly require declared provenance and consistent sensorial performance, and pharmaceuticals, where adjuvant manufacturers and CMOs prioritize validated quality and secure supply, often through regional ingredient distributors for cosmetics and direct qualification-based supply for pharma accounts.

Market Opportunities and Future Outlook

A clear whitespace sits at the intersection of sustainability and parenteral-grade performance, where demand for adjuvant-ready squalene favors suppliers that can document traceability while meeting stringent impurity limits and batch consistency. Existing commercial activity reflects this direction. Croda's exclusive licensing arrangement with Amyris for biotechnology-derived, pharmaceutical-grade squalene and Evonik's GMP-grade, plant-based PhytoSquene both position suppliers around vaccine-adjuvant requirements rather than only cosmetic emollients. Process innovations that compress manufacturing timelines also support alternative models for GMP capacity, as microfluidic adjuvant manufacturing demonstrations (reported in 2024) reduced batch time and improved capital efficiency for producing GMP emulsions, widening the set of qualified producers beyond traditional large sites.

Technology-led opportunities continue to develop in microbial platforms and strain engineering, targeting higher titers and lower unit costs while maintaining non-animal sourcing. Published research in January 2026 demonstrated enhanced squalene production in Yarrowia lipolytica through metabolic engineering and adaptive laboratory evolution, with broader academic work also validating industrial feasibility in microbial hosts such as thraustochytrids (e.g., Thraustochytrium and Aurantiochytrium). For cosmetics, provenance-flexible, plant-based emollients create an additional adoption pathway in markets with stricter standards, including launches positioned for Japanese quasi-drug requirements and expanded distributor coverage in Oceania. Together, these moves support scaling plant-derived portfolios while reducing dependency on volatile single-crop supply.